RT Journal Article
SR Electronic
T1 CAPICE: a computational method for Consequence-Agnostic Pathogenicity Interpretation of Clinical Exome variations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 19012229
DO 10.1101/19012229
A1 Li, Shuang
A1 van der Velde, K. Joeri
A1 de Ridder, Dick
A1 van Dijk, Aalt D.J.
A1 Soudis, Dimitrios
A1 Zwerwer, Leslie R.
A1 Deelen, Patrick
A1 Hendriksen, Dennis
A1 Charbon, Bart
A1 van Gijn, Marielle
A1 Abbott, Kristin M.
A1 Sikkema-Raddatz, B.
A1 van Diemen, Cleo C.
A1 Kerstjens-Frederikse, Wilhelmina S.
A1 Sinke, Richard J.
A1 Swertz, Morris A.
YR 2019
UL http://medrxiv.org/content/early/2019/11/29/19012229.abstract
AB Exome sequencing is now mainstream in clinical practice, however, identification of pathogenic Mendelian variants remains time consuming, partly because limited accuracy of current computational prediction methods leaves much manual classification. Here we introduce CAPICE, a new machine-learning based method for prioritizing pathogenic variants, including SNVs and short InDels, that outperforms best general (CADD, GAVIN) and consequence-type-specific (REVEL, ClinPred) computational prediction methods, for both rare and ultra-rare variants. CAPICE is easily integrated into diagnostic pipelines and is available as free and open source command-line software, file of pre-computed scores, and as a web application with web service API.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project has received funding from the Netherlands Organisation for Scientific Research NWO under VIDI grant number 917.164.455.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCAPICE is available as a free and open source software command-line tool from https://github.com/molgenis/capice and as a web-app at https://molgenis43.gcc.rug.nl/. Pre-computed scores are available as a download at https://doi.org/10.5281/zenodo.3516248